6582-45-2

Basic information

• Product Name: 1-Butanone, 1-(3,4-dichlorophenyl)-
• Synonyms: 1-Butanone, 1-(3,4-dichlorophenyl)-
• CAS NO: 6582-45-2
• Molecular Formula: C₁₀H₁₀Cl₂O
• Molecular Weight: 217.0918
• Mol File: 6582-45-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Butanone, 1-(3,4-dichlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanone, 1-(3,4-dichlorophenyl)-(6582-45-2)
• EPA Substance Registry System: 1-Butanone, 1-(3,4-dichlorophenyl)-(6582-45-2)

Safety Data

• Hazardous Substances Data: 6582-45-2(Hazardous Substances Data)

Usage

Type of compound

Derivative of butanone (a ketone)

Contains

3,4-dichlorophenyl group

Uses

Intermediate in the synthesis of pharmaceuticals and agrochemicals, potential applications as a pesticide and herbicide

Hazards

Harmful if ingested, inhaled, or absorbed through the skin, may cause irritation to the eyes, skin, and respiratory system.

Upstream product

• 6574-99-8 3,4-dichloro-benzonitrile 
• 2234-82-4 1-propylmagnesium chloride 
• 766-84-7 3-chloro-benzonitrile 
• 557-93-7 2-bromoprop-1-ene 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 801154-23-4 (+/-)-1-Isopropylamino-1-<3.4-dichlor-benzoyl>-propan 
• 850352-47-5 2-bromo-1-(3,4-dichlorophenyl)butan-1-one 
• 90944-02-8 α-<3,4-Dichlor-phenyl>-n-butylamin 
• 847448-19-5 {[1-(3,4-dichloro-phenyl)-butyl]-formyl-amino}-acetic acid methyl ester 

Relevant articles and documents

Conversion of Aldehydes to Branched or Linear Ketones via Regiodivergent Rhodium-Catalyzed Vinyl Bromide Reductive Coupling-Redox Isomerization Mediated by Formate

A regiodivergent catalytic method for direct conversion of aldehydes to branched or linear alkyl ketones is described. Rhodium complexes modified by PtBu2Me catalyze formate-mediated aldehyde-vinyl bromide reductive coupling-redox isomerization to form branched ketones. Use of the less strongly coordinating ligand, PPh3, promotes vinyl-to allylrhodium isomerization en route to linear ketones. This method bypasses the 3-step sequence often used to convert aldehydes to ketones involving the addition of pre-metalated reagents to Weinreb or morpholine amides.

Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction

A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a 1a analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [3H] dopamine ([3H]DA), [3H]serotonin ([3H]5HT), and [3H]norepinephrine ([3H]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [125I]RTI-55 in cloned transporters. Several analogues showed increased [3H]DAuptake inhibition with reduced or little change in [3H]5HT and [3H]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a time course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3- chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction. 2009 American Chemical Society.

PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF

New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R-or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.